Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines

Vaccine

Volumn 25, Issue 25, 2007, Pages 4809-4817

  Ferrier Rembert, Audrey ^a   Drillien, Robert ^b   Tournier, Jean Nicolas ^a   Garin, Daniel ^a   Crance, Jean Marc ^a  

^a Centre de Recherches   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cowpox virus; Mouse model; Smallpox vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COWPOX VIRUS VACCINE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COWPOX VIRUS; DOSE TIME EFFECT RELATION; EARLY DIAGNOSIS; FEMALE; IMMUNOGENICITY; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELEVANCE VECTOR MACHINE; SMALLPOX; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; COWPOX; COWPOX VIRUS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNITY, CELLULAR; LUNG; LYMPHOCYTES; MICE; SMALLPOX VACCINE; SPLEEN; VIRUS REPLICATION;

EID: 34249744721     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.011     Document Type: Article

References (27)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication (1988), WHO, Geneva
2. Working Group on Civilian Biodefense, Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Jama 281 22 (1999) 2127-2137
3. Fenner F., and Smallpox. The most dreadful scourge of the human species. Its global spread and recent eradication (2). Med J Aust 141 11 (1984) 728-735
4. Cono J., Casey C.G., and Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 52 RR-4 (2003) 1-28
5. Lane J.M., Ruben F.L., Neff J.M., and Millar J.D. Complications of smallpox vaccination, 1968. N Engl J Med 281 22 (1969) 1201-1208
6. Neff J.M., Lane J.M., Fulginiti V.A., and Henderson D.A. Contact vaccinia-transmission of vaccinia from smallpox vaccination. Jama 288 15 (2002) 1901-1905
7. Cohen J., and Bioterrorism. Smallpox vaccinations: how much protection remains?. Science 294 5544 (2001) 985
8. Alibek K. The Soviet Union's anti-agricultural biological weapons. Ann N Y Acad Sci 894 (1999) 18-19
9. Orent W. Escape from moscow. Science 3 (1998) 26-31
10. EMEA. Note for guidance on the development of vaccinia virus based vaccines against smallpox. 2002.
11. Smee D.F., Bailey K.W., and Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 12 1 (2001) 71-76
12. Smee D.F., Bailey K.W., Wong M., and Sidwell R.W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res 47 3 (2000) 171-177
13. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., and Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 181 1 (2000) 10-19
14. Fang M., and Sigal L.J. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 175 10 (2005) 6829-6836
15. Zaucha G.M., Jahrling P.B., Geisbert T.W., Swearengen J.R., and Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81 12 (2001) 1581-1600
16. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79 12 (2005) 7845-7851
17. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 7 (2005) 740-747
18. Smee D.F., and Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 57 1-2 (2003) 41-52
19. Bray M., Martinez M., Kefauver D., West M., and Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 54 3 (2002) 129-142
20. Leparc-Goffart I., Poirier B., Garin D., Tissier M.H., Fuchs F., and Crance J.M. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J Clin Virol 32 1 (2005) 47-52
21. Tscharke D.C., and Smith G.L. A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80 Pt 10 (1999) 2751-2755
22. Tournier J.N., Hellmann A.Q., Lesca G., Jouan A., Drouet E., and Mathieu J. Fever-like thermal conditions regulate the activation of maturing dendritic cells. J Leukoc Biol 73 4 (2003) 493-501
23. Hamilton M.A., Russo R.C., and Thurston R.V. Trimmed Spearman-Karber method for estimating median lethal concentration in toxicity bioassays. Environ Sci Technol 11 7 (1977) 714-719
24. Martinez M.J., Bray M.P., and Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med 124 3 (2000) 362-377
25. Phelps A., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Vaccine 23 27 (2005) 3500-3507
26. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 2 (2005) 164-175
27. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101